期刊
JOURNAL OF MEDICINAL CHEMISTRY
卷 62, 期 18, 页码 8544-8556出版社
AMER CHEMICAL SOC
DOI: 10.1021/acs.jmedchem.9b00911
关键词
-
资金
- Wellcome Trust
- Cancer Research U.K.
- Medical Research Council
- Biotechnology and Biological Research Council [BB/S50676X/1]
- Innovative Medicines Initiative (European Lead factory)
- Innovative Medicines Initiative (ENABLE components)
- National Institute of Allergy and Infectious Diseases of the National Institutes of Health [RO1Al100560]
- Engineering and Physical Sciences (EPSRC) Research Councils [BB/L01386X/1]
- BBSRC ALERT14 equipment initiative [BB/M012107/1]
- BBSRC [BB/K017268/1, BB/L01386X/1, 1801761, BB/M012107/1] Funding Source: UKRI
- MRC [G1100135, MR/N002679/1] Funding Source: UKRI
The bicyclic boronate VNRX-5133 (taniborbactam) is a new type of beta-lactamase inhibitor in clinical development. We report that VNRX-5133 inhibits serine-beta-lactamases (SBLs) and some clinically important metallo-beta-lactamases (MBLs), including NDM-1 and VIM-1/2. VNRX-5133 activity against IMP-1 and tested B2/B3 MBLs was lower/not observed. Crystallography reveals how VNRX-5133 binds to the class D SBL OXA-10 and MBL NDM-1. The crystallographic results highlight the ability of bicyclic boronates to inhibit SBLs and MBLs via binding of a tetrahedral (sp(3)) boron species. The structures imply conserved binding of the bicyclic core with SBLs/MBLs. With NDM-1, by crystallography, we observed an unanticipated VNRX-5133 binding mode involving cyclization of its acylamino oxygen onto the boron of the bicyclic core. Different side-chain binding modes for bicyclic boronates for SBLs and MBLs imply scope for side-chain optimization. The results further support the high-energy-intermediate analogue approach for broad-spectrum beta-lactamase inhibitor development and highlight the ability of boron inhibitors to interchange between different hybridization states/binding modes.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据